Abilify and Treximet drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Abilify (aripiprazole) and Treximet (naproxen sodium; sumatriptan succinate). Common drug interactions include anxiety among females.

The phase IV clinical study analyzes what interactions people have when they take Abilify and Treximet. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Abilify?

Abilify has active ingredients of aripiprazole. It is often used in depression. eHealthMe is studying from 101,456 Abilify users. Check the latest studies of Abilify.

What is Treximet?

Treximet has active ingredients of naproxen sodium; sumatriptan succinate. It is often used in migraine. eHealthMe is studying from 1,904 Treximet users. Check the latest studies of Treximet.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 02, 2026

12 people who take Abilify and Treximet together, and have interactions are studied.

Abilify and Treximet drug interactions.

What are the common drug interactions of Abilify and Treximet, by gender? *:

female:

  1. Anxiety
  2. Biliary dyskinesia (motility disorder that affects the gallbladder and sphincter of oddi)
  3. Burning sensation
  4. Chronic kidney disease
  5. Disturbance in attention
  6. Drug ineffective
  7. Dyskinesia (abnormality or impairment of voluntary movement)
  8. Headache (pain in head)
  9. Heart rate increased
  10. Hot flush (sudden feelings of heat)

male:

n/a

What are the common drug interactions of Abilify and Treximet, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Biliary dyskinesia (motility disorder that affects the gallbladder and sphincter of oddi)
  2. Gallbladder disorder
  3. Organ failure
  4. Dry mouth
  5. Dyskinesia (abnormality or impairment of voluntary movement)
  6. Injury
  7. Pain
  8. Salivary hypersecretion (excess saliva secretion)

30-39:

n/a

40-49:

  1. Abdominal discomfort
  2. Akathisia (a movement disorder characterized by a feeling of inner restlessness)
  3. Anxiety
  4. Burning sensation
  5. Diarrhoea
  6. Fatigue (feeling of tiredness)
  7. Headache (pain in head)
  8. Heart rate increased
  9. Malaise (a feeling of general discomfort or uneasiness)
  10. Mental impairment (a condition affecting the body, perhaps through sight or hearing loss, a mobility difficulty or a health condition)

50-59:

  1. Hot flush (sudden feelings of heat)
  2. Lacrimation increased
  3. Insomnia (sleeplessness)
  4. Anxiety
  5. Diarrhoea
  6. Disturbance in attention
  7. Drug ineffective
  8. Fatigue (feeling of tiredness)

60+:

  1. Chronic kidney disease
  2. Renal failure (kidney dysfunction)
  3. Renal injury (kidney injury)
  4. Tubulointerstitial nephritis (a form of nephritis affecting the interstitium of the kidneys surrounding the tubules)

What are the existing conditions these people have? *

  1. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 3 people, 25.00%
  2. Cataplexy (loss of muscle tone accompanied by full conscious awareness): 3 people, 25.00%
  3. Amenorrhea (absence of a menstrual period in a woman of reproductive age): 2 people, 16.67%
  4. Bipolar Disorder (mood disorder): 2 people, 16.67%
  5. Osteoporosis (bones weak and more likely to break): 2 people, 16.67%
  6. Generalized Anxiety Disorder (excessive, uncontrollable, unexplained and often irrational worry): 1 person, 8.33%
  7. Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 8.33%
  8. Birth Control: 1 person, 8.33%
  9. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 8.33%
  10. Thyroid Diseases: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Abilify and Treximet?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Abilify and Treximet:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Abilify:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Treximet:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Abilify and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Treximet and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on aripiprazole and naproxen sodium; sumatriptan succinate (the active ingredients of Abilify and Treximet, respectively), and Abilify and Treximet (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: